Clinical research backed by the EU is bringing life-saving medicines and health tools to sub-Saharan Africa. This success story offers a valuable lesson as negotiations get underway on the next research programme

It is promised as the most important update for more than twenty years, but tensions are high as MEPs struggle to reach a compromise over the EU’s proposed pharmaceutical reform

Research commissioned by lobby group EFPIA shows Germany, Belgium and France will be among those hit hardest if the Commission’s proposals go ahead. In total, R&D would be cut by €2B per annum

Forty new rare disease programmes entering the clinic over the next decade. This is the goal of a new collaboration between Oxford University and the Harrington Discovery Institute, which aims to put up to £200M into getting projects out academic labs and into clinical development  

Long-awaited Commission proposals to reform EU’s pharmaceutical legislation seek to improve access to medicines and promote innovation, but companies say they will drive investment out of Europe

Already overdue, the new pharmaceutical strategy will not be published tomorrow as promised. The Commission says the proposal will arrive ‘slightly later’, as tensions fly high over how to incentivise industrial R&D

The latest figures on R&D funding for neglected diseases show the EU is making its greatest contribution to date. But looking at the big picture it’s clear more needs to be done to tackle diseases that affect millions of people around the world

Greater integration between research and technology transfer at Cancer Research UK is supporting the formation of more start-ups and fostering the development of an international network of academic partners with complementary skills and capabilities

European Commission helps raise €7.4B to fund global research on vaccines and treatments for COVID-19, but warns this sum represents only a “great start” to funding needed to deal with the pandemic

Funding vaccine, drug and diagnostic development is the world’s one exit strategy from the pandemic